Evidence map›Paper›PMID 41853208›Full record

ArticleRSC advances2026

Enhancing Veliparib PARP1 inhibitor stability against UVC degradation

Carlota J F Conceição, Elin Moe, Paulo A Ribeiro, Maria Raposo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carlota J F ConceiçãoLaboratory of Instrumentation, Biomedical Engineering and Radiation Physics (LIBPhys-UNL), LA-REAL, Department of Physics, NOVA School of Science and Technology, Universidade NOVA de Lisboa 2829-516 Caparica Portugal mfr@fct.unl.pt.
Elin MoeITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa 2780-157 Oeiras Portugal.ORCID https://orcid.org/0000-0002-7923-1471
Paulo A RibeiroLaboratory of Instrumentation, Biomedical Engineering and Radiation Physics (LIBPhys-UNL), LA-REAL, Department of Physics, NOVA School of Science and Technology, Universidade NOVA de Lisboa 2829-516 Caparica Portugal mfr@fct.unl.pt.
Maria RaposoLaboratory of Instrumentation, Biomedical Engineering and Radiation Physics (LIBPhys-UNL), LA-REAL, Department of Physics, NOVA School of Science and Technology, Universidade NOVA de Lisboa 2829-516 Caparica Portugal mfr@fct.unl.pt.ORCID https://orcid.org/0000-0003-4710-0693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly(ADP-ribose) polymerase inhibitors (PARPi) are often used in complementary cancer therapy with radiotherapy and chemotherapy, but present some limitations that encapsulation may circumvent. Since conventional PARPi therapy was proven to increase cell sensitization to UV irradiation, and a shower of particles or radiation with energies equal to or below UV can be created during radiotherapy treatments, this work evaluates the effect of UVC on the degradation process and inhibitory capability of Veliparib encapsulated in 1,2-dipalmitoyl-

Identifiers

PMID41853208
PMCPMC12994379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.